C4 Therapeutics定价1.25亿美元股票发行认股权证

2025-10-16 19:27

C4 Therapeutics (NASDAQ:CCCC) priced an offering of 21.9M shares and 28.7M pre-funded warrants, each paired with Class A and Class B Warrants.
Securities priced at $2.47/share or $2.4699/pre-funded warrant, with Class A and B Warrants exercisable at $2.22/share.
Class A Warrants expire after 30 days post-clinical trigger or in 5 years; Class B Warrants expire in 5 years, with possible mandatory exercise conditions.
Gross proceeds will be $125M initially, and up to $349.7M if all warrants are exercised.
Proceeds will fund clinical trials of cemsidomide, R&D activities, and general corporate needs.
Offering expected to close on or around October 17, 2025.
CCCC shares down 4.5% premarket on Thursday.

More on C4 Therapeutics